Abstract. Selenium intake (5.0 ppm) induces growth retardation, accumulation of selenium in somatotrophs, lack of growth hormone response to GHRH and an 80 per cent reduction in serum somatomedin C in infant rats. In addition, it induces a slight reduction in serum albumin and occasionally slight central liver necrosis. In order to determine the role of insufficient growth hormone production, the influence of exogenous growth hormone was studied during selenium intake in groups of rats during 25 to 46 days of age (post-weaning). A dosage of human growth hormone (100 \ g=m\ g twice daily) was chosen, this being sufficient to restore normal growth rate and normal serum somatomedin C in hypophysectomized rats of similar age. The weight gain in selenium-treated (3.3 ppm) rats was 46.0 \m=+-\11.7 g (sd)/21 days, whereas in selenium rats given growth hormone it was 66.6 \m=+-\8.9 g (P = 0.01), which was similar to the gain in control rats 72.3 \m=+-\6.9 g. The latter two were less than the weight gain in control rats given growth hormone: 91.5 \m=+-\11.5 g (P = 0.01 and P < 0.01). Serum somatomedin C in untreated rats was 151 \m=+-\66(SD) \g=m\g/l (25 days) increasing to 532 \m=+-\ 91 \ g=m\ g/ l (34 days) and 482 \ m=+-\64 \g=m\g/l(46 days). It did not increase above these levels in control rats given growth hormone. In selenium-treated rats, no increase occurred during growth hormone administration 138 \m=+-\148 \ g=m\ g/ l (34 days) and 185 \m=+-\84 \g=m\g/l(46 days) (P < 0.001 and P < 0.001 vs untreated controls). Furthermore, there was no reduction in serum protein or albumin and no liver necrosis in these selenium-treated rats. As exogenous administration of growth hormone normalizes weight gain, the results indicate that growth retardation is at least partly due to insufficient growth hormone production. The increased growth rate in seleniumtreated and control rats given growth hormone appears to be independent or circulating somatomedin C. This may be a direct effect of growth hormone or, more likely, may be caused by GH stimulation of peripheral (paracrine) formation of growth factors, possibly somatomedin C.
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Although selenium is an essential trace element (Schwarz & Foltz 1957; Rotruck et al. 1973) , it is also a most toxic agent when recommended doses are exceeded and these are not firmly established in animals and man. Selenium has acute toxic effects characterized by impaired CNS function, heart failure, and liver necrosis, but may also induce two forms of more chronic toxicity, de¬ pending on exposure (Shamberger 1983a) . 'Alkali disease' is seen in animals exposed to 5-40 ppm of selenium in food or drinking water (Franke & Potter 1935; Moxon 1937) . In young rats, a strik¬ ing phenomenon is growth retardation, but anae¬ mia and liver necrosis may also be observed (Franke 8c Potter 1935; Moxon 1937; Halverson et al. 1966; Palmer & Olson 1974) . The other chronic toxicity, 'blind staggers disease', is rare and seen in livestock after consumption of seleni¬ um-containing plants, resulting in very high ex¬ posure (40-10 000 ppm) (Shamberger 1983a (J0rgensen 1987) . Weights were identical at onset of the experiment.
Blood was sampled in all rats when 34 and 46 days old. The first sample (0.7 ml) was collected from the retrobulbar venous plexus through a heparinized capil¬ lary tube. At (Fig. 1) . The initial weights (day 24) of the four groups were: selenium rats 44.2 ± 6.3 g (SD); selenium + GH rats 41.0 ± 11.0 g; control rats 48.7 ± 6.5; control + GH rats 42.3 ± 6.4 g. Flg. 1. Growth rate (± SD) in the four groups. Group 1: sele¬ nium-treated rats; group 2: selenium-and hGH-treated rats; group 3: untreated control rats; group 4: control rats treated with hGH (100 µg twice daily).
Growth rate in hypophysectomized rats Fig. 2 demonstrates that a 24- The dose-response curve is shown in Fig. 3 . The curve is steep at low doses and then levels off with increased doses. The saline-treated rats gained 2.2 ± 2.0 g (SD) during the treatment period. The log dose response line is also depicted in Fig. 3 The mean coefficients of variation are: 6.7 ± 0.7; 6.8 ± 0.5; 5.0 ± 0.4; 5.1 ± 0.4; 5.9 ± 0.7; 5.6 ± 0.7; 6.2 ± 7.4% for the growth rates read from below. Serum somatomedin C immunoreactivity in untreated rats at start of experiment (day 25, = 15) and at day 34 and 46 after selenium and saline treatment (group 1, = 6) selenium and hGH treatment (group 2, = 6) saline treatment (group 3, = 6), and hGH treatment ( 100 µg twice daily, group 4, = 6).
Discussion
This study shows that growth hormone admini¬ stration restores growth in post-weaning seleni¬ um-treated rats, which points to selenium inhibi¬ tion at the pituitary level, resulting in growth hormone deficiency. It is, however, interesting that selenium apparently also induces an inde¬ pendent inhibition of the SMC production, as the animals in the two selenium-treated groups had very low plasma levels irrespective of hGH treat¬ ment. A possible explanation is an attempted incorporation of selenium instead of sulphur in either SMC or the enzymes responsible for its production, as the metabolisms of selenium and sulphur have much in common (Shamberger 1983b) . Another possibility is an oxidation of sulphur groups in these proteins, as selenium is known to exert such a process. Indeed, this has been suggested to be the major toxic effect of selenium (Shamberger 1983a Salmon & Daughaday (1957) and Daughaday et al. (1972) . It concurs, however, with reports that local administration of hGH and rGH into the cartilage growth plate of the proximal tibia accele¬ rates longitudinal bone growth (Isaksson et al. 1982; Rüssel & Spencer 1985) Zezulak & Green (1986) in vitro in pre-adipocyte cultures. The GH-treated sele¬ nium rats did not reach the weight gain of GHtreated controls, and so some inhibition of peri¬ pheral synthesis of somatomedin may occur in selenium-treated rats.
In the hypophysectomized rats, hGH increased plasma SMC in a dose-dependent manner until further increase became very small at normal levels around 500 µg/l after injection of 32-64 µg of hGH twice daily. In the selenium study, we more than tripled the dose, indicating that lack of SMC production is not due to insufficient stimula¬ tion. This study supports the notion that SMC production is age-dependent, as an impressive increase in SMC from about 150 µg/l post weaning to about 500 µg/l between day 25 and 34 was observed, whereas no further increase was obtained during the remaining experimental per¬ iod which lasted until day 46. This level is close to that observed in the hypophysectomized rats ex¬ posed to 62 µg of hGH, the particular dosage that restored weight gain to normal. The control rats at this age have probably reached a SMC produc¬ tion which requires very large growth hormone doses to increase significantly (Fig. 4) .
In conclusion, these results indicate that growth retardation in selenium-treated rats is due pri¬ marily to insufficient growth hormone produc¬ tion, as this retardation is overcome by admini¬ stration of exogenous GH. Incidentally, we found indications that hepatic somatomedin C produc¬ tion is also directly inhibited during selenium intake, and also that normal growth rate may be restored without increase in serum SMC immuno¬ reactivity, but through other effects of GH, prob¬ ably through stimulation of somatomedin forma¬ tion in the periphery. The results thus also sug¬ gest that the growth retardation observed in rats exposed to moderate selenium intake is not due to anorexia or gross liver damage. The inhibited production of sulphur-containing peptides such as hepatic somatomedin C and GH at a vulnerable period of life is in accordance with the finding of particularly great accumulations of selenium in liver and somatotrophs (Shamberger 1983a) .
Selenium is becoming increasingly popular as an ingredient in vitamin/mineral tablets and in alternative medicine recipes, because of a cancer prophylactic effect which is undocumented in man. The growth retarding effect of selenium and the observation of severely reduced GH and hepatic SMC production in infant rats highlight the need for human studies.
